Bitcoin price today: little changed near $119k ahead of Fed meet, tariff deadline
Christopher J. Joyce, the Chief Legal and Administrative Officer at Alignment Healthcare, Inc. (NASDAQ:ALHC), a $3.4 billion healthcare company whose stock has surged 270% over the past year, recently sold 25,000 shares of the company’s common stock. The transaction took place on April 1, 2025, as part of a pre-established trading plan adopted on November 27, 2024. The shares were sold at a weighted-average price of $18.4653, with individual sale prices ranging between $18.14 and $18.84. Following this sale, Joyce retains ownership of 415,022 shares in the company. The stock currently trades near its 52-week high, with analysts setting price targets between $9 and $21. InvestingPro analysis reveals 10+ additional exclusive insights about ALHC’s valuation and growth prospects, including detailed insider trading patterns and comprehensive Fair Value assessments.
In other recent news, Alignment Healthcare has reported impressive fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16, compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. This performance marks the company’s first year of adjusted EBITDA profitability, with total revenue for 2024 reaching $2.7 billion, a 48% increase year-over-year. Piper Sandler recently raised its price target for Alignment Healthcare to $21, maintaining an Overweight rating, citing confidence in the company’s scalable business model and high Star Ratings. Similarly, Raymond (NSE:RYMD) James increased its price target to $19, maintaining a Strong Buy rating after the company posted a membership growth of approximately 59% and a 51% increase in top-line growth. Looking forward, Alignment Healthcare has provided guidance for 2025, projecting revenue between $3.72 billion and $3.78 billion, with an expected growth in Health Plan Membership to between 227,000 and 233,000 members. The company anticipates adjusted gross profit to range from $415 million to $445 million, with adjusted EBITDA guidance raised to between $35 million and $60 million. Analysts from Raymond James have highlighted the company’s ability to grow at a rate of 20% or more annually while enhancing EBITDA profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.